Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NBTX 
Nanobiotix (NBTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NBTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.61
1 Year Target Price $7.61
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 100.11% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 442.79M USD | Price to earnings Ratio - | 1Y Target Price 7.61 |
Price to earnings Ratio - | 1Y Target Price 7.61 | ||
Volume (30-day avg) 4 | Beta 1.5 | 52 Weeks Range 2.76 - 10.59 | Updated Date 08/29/2025 |
52 Weeks Range 2.76 - 10.59 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-09-04 | When - | Estimate -0.3529 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 271.42% |
Management Effectiveness
Return on Assets (TTM) -52.89% | Return on Equity (TTM) -198.69% |
Valuation
Trailing PE - | Forward PE 48.31 | Enterprise Value 436699169 | Price to Sales(TTM) 3.82 |
Enterprise Value 436699169 | Price to Sales(TTM) 3.82 | ||
Enterprise Value to Revenue 3.39 | Enterprise Value to EBITDA -2.45 | Shares Outstanding 47921000 | Shares Floating 24668475 |
Shares Outstanding 47921000 | Shares Floating 24668475 | ||
Percent Insiders - | Percent Institutions 11.9 |
Upturn AI SWOT
Nanobiotix
Company Overview
History and Background
Nanobiotix was founded in 2003. It focuses on developing nanoparticle-based cancer therapies. The company's lead product, NBTXR3, aims to enhance the efficacy of radiotherapy.
Core Business Areas
- Nano-Oncology: Development and commercialization of nanoparticle-based therapies to improve cancer treatment outcomes.
Leadership and Structure
Laurent Levy is the CEO. The company has a structured management team overseeing research, clinical development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- NBTXR3: A nanoparticle drug designed to enhance the effectiveness of radiotherapy in cancer treatment. Currently approved in Europe and under development for other markets. Competitors include traditional radiotherapy and other emerging cancer therapies. Revenue data is not publicly available
Market Dynamics
Industry Overview
The oncology market is large and growing, with increasing demand for effective and targeted cancer therapies. Radiation oncology is a vital part of cancer care. The market is competitive but with space for innovative technologies.
Positioning
Nanobiotix aims to differentiate itself through its unique nanoparticle technology that enhances radiotherapy. Its competitive advantage lies in potentially improving treatment outcomes and expanding the applicability of radiation therapy.
Total Addressable Market (TAM)
The global radiotherapy market is substantial, estimated to be in the billions of dollars. Nanobiotix targets a segment of this market by enhancing radiotherapy efficacy.
Upturn SWOT Analysis
Strengths
- Innovative nanoparticle technology
- Potential to improve radiotherapy outcomes
- Approved product in Europe (NBTXR3)
- Strong IP portfolio
Weaknesses
- Limited commercial infrastructure
- Reliance on clinical trial success
- High development costs
- Limited product pipeline
Opportunities
- Expansion into new markets (US)
- Development of new applications for NBTXR3
- Partnerships with pharmaceutical companies
- Combination therapies with other cancer treatments
Threats
- Competition from established cancer therapies
- Regulatory hurdles
- Clinical trial failures
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- Varian Medical Systems (VAR)
- Elekta AB (EKTAY)
- Accuray Incorporated (ARAY)
Competitive Landscape
Nanobiotix's advantages lie in its novel technology, whereas competitors have established market presence and infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily characterized by R&D progress and clinical trial advancements.
Future Projections: Future growth depends on successful commercialization of NBTXR3 and expansion into new indications.
Recent Initiatives: Recent initiatives include clinical trial progress, regulatory submissions, and market access efforts.
Summary
Nanobiotix is a developmental-stage company with a novel technology that enhances radiotherapy. Successful clinical trials in the US are needed to drive the stock forward. The company needs to improve infrastructure and reduce development costs. Current competitors are much larger and more established than Nanobiotix.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated based on available resources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nanobiotix
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-12-11 | Co-Founder, President of the Executive Board & CEO Mr. Laurent Levy Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 108 | Website https://www.nanobiotix.com |
Full time employees 108 | Website https://www.nanobiotix.com | ||
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.